Bausch & Lomb cuts jobs again:
This article was originally published in Clinica
Executive Summary
Ophthalmic company Bausch & Lomb is to cut around 700 jobs as part of restructuring measures aimed to reducing operating costs. The cuts, which are the fourth set of job losses at the company since late 1999, will affect all regions and functional units, the company says. B&L has been hit by lower demand for its laser eye surgery products and has been forced to issue several profit warnings in recent years.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.